Imbruvica logo

Menu

  • Home
  • IMBRUVICA® CLL/SLL Cost

Coverage and Cost

When you have support, such as help understanding your insurance coverage and potential ways to pay for IMBRUVICA®, you may feel more confident during treatment. The YOU&i™ Support Program is here to help answer some of your questions about the financial aspects of taking IMBRUVICA®.

Learn more about your insurance coverage and potential financial support options. 

HCP Patient icon

Call the YOU&i™ Support Program

1-877-877-3536 | Menu Option 1

Monday-Friday, 8:00am-8:00pm and Saturday, 8:00am-5:00pm ET

IMBRUVICA® Copay Program 

If you have commercial insurance, you could get IMBRUVICA® for as little as

$10
per prescription*

*Eligible patients may qualify to pay $10 per prescription of IMBRUVICA® until the maximum limit of $24,600 per calendar year is reached. The IMBRUVICA® Copay Program cannot be used with any other federally-funded prescription insurance plan. Federally-funded plans include Medicare Part D, Medicare Advantage Plan, Medicaid, TRICARE, or any other federal or state healthcare plan, including pharmaceutical assistance programs.

Enroll in the IMBRUVICA Copay Program

Wholesale Acquisition Cost (WAC)

The Wholesale Acquisition Cost (WAC), also known as the list price, 30-day supply of IMBRUVICA® is $13,892.25 as of January 2020. A majority of patients do not pay full list price once insurance coverage is applied.

The list price for a 30-day supply of IMBRUVICA® (ibrutinib) 420-mg tablets, which is the recommended dose for CLL.

Understanding Insurance for CLL Patients

If you have: You could pay:
Commercial Insurance (usually provided by an employer) As little as $10 per month* with the IMBRUVICA® Copay Program. Learn More and Enroll Here
Medicare (Part D and LIS)

Most patients with Medicare pay between $0 and $53 per month for IMBRUVICA® in CLL. This number represents Medicare Part D, including those with LIS. Actual out-of-pocket costs may vary based on dosing, indication, site of care, insurance coverage, and your eligibility for support programs (some of which require you to apply for the support, like independent charitable foundations).

The information below is based on the benefit structure for Medicare Part D and LIS. Please see Medicare.gov for more information.

Medicare Part D

Most Medicare patients have standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. With standard Part D prescription coverage, you could pay $695 - $2,881 per month, depending on coverage phase. Monthly out-of-pocket costs for IMBRUVICA® may vary depending on coverage phase and other medications you may be taking.

Medicare Low Income Subsidy

Eligible patients may be able to access Brand name drugs for less than $10 per month. You may be eligible for the Extra Help program provided by the Social Security Administration.

We can help you understand what these costs mean to you by calling 1-877-877-3536 (Menu Option 1).

Medicaid, including Fee-for-Service and Managed The information below is based on the benefit structure for Medicaid. Please see Medicaid.gov for more information.

$8.00 or less per month, depending on state plan.

Other Insurance (VA, DOD, Tricare, others) Because coverage varies by plan, call 1-877-877-3536 (Menu Option 1) to find out how much IMBRUVICA® will cost for you.
Uninsured or if you cannot afford your medication Pharmacyclics and Janssen are committed to helping the uninsured gain access to our medicine. Call 1-877-877-3536 (Menu Option 1) or visit www.pparx.org for assistance.

Important Details About Understanding Your Individual Costs:

Your type of health or prescription insurance plan will determine exactly how much you will pay. The benefit structure is based on the publicly available information for Medicare Part D, LIS, and Medicaid and cost is accurate as of January 2020 for a 30-day supply of IMBRUVICA® (420-mg dose).

*Eligible patients may qualify to pay $10 per prescription of IMBRUVICA® until the maximum limit of $24,600 per calendar year is reached. The IMBRUVICA® Copay Program cannot be used with any other federally-funded prescription insurance plan. Federally-funded plans include Medicare Part D, Medicare Advantage Plan, Medicaid, TRICARE, or any other federal or state healthcare plan, including pharmaceutical assistance programs.

Approximately 75% of US patients in this category pay an amount in this range. Actual out-of-pocket costs may vary based on dosing, indication, site of care, insurance coverage, and your eligibility for support programs (some of which require you to apply for the support, like independent charitable foundations). Contact your insurance provider for more details on your individual plan. Out-of-pocket cost estimates are based on approved pharmacy claims, normalized to a 30-days’ supply, after application of insurance benefits. Costs do not include medical claims and starter kits. Note: This is based on information licensed from IQVIA™: IQVIA™ Out of Pocket Cost (OPC Tool) for the period September 2019 – August 2020, reflecting estimates of real-world activity. All rights reserved.



No matter what type of insurance plan you have, or if you don't have insurance, the YOU&i™ Support Program can help you understand your coverage and potential financial support options for IMBRUVICA®.

Phone icon

1-877-877-3536 | Menu Option 1

Clock icon

Monday-Friday, 8:00 am-8:00 pm and Saturday, 8:00am-5:00pm ET

Other resources

Johnson & Johnson Patient Assistance Foundation, Inc.

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if you might qualify for assistance, please contact a JJPAF program specialist at 800-652-6227 (Monday – Friday, 9:00 AM to 6:00 PM ET) or visit the foundation website at JJPAF.org.

YOU&i Logo

The YOU&i™ Support Program is with you along the way.

Sign Up for Support

IMPORTANT SIDE EFFECT INFORMATION

Before taking IMBRUVICA®, tell your healthcare provider about all of your medical 
conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
  • have bleeding problems. 
  • have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes.
  • have an infection.
  • have liver problems.
  • are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA®. 
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA® and for 1 month after the last dose.
    • Males with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose.
  • are breastfeeding or plan to breastfeed.  Do not breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose. 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

  • Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
  • Take IMBRUVICA® 1 time a day.
  • Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
  • Do not open, break or chew IMBRUVICA® capsules.
  • Do not cut, crush or chew IMBRUVICA® tablets.
  • Take IMBRUVICA® at about the same time each day.
  • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
  • If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away. 

What should I avoid while taking IMBRUVICA®?

  • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

  • Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.  
  • Infections can happen during treatment with IMBRUVICA®.  These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
  • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe.  Your healthcare provider should do monthly blood tests to check your blood counts.
  • Heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter). Serious heart rhythm problems and death have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint.  If you develop any of these symptoms, your healthcare provider may do a test to check your heart (ECG) and may change your IMBRUVICA® dose.
  • High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
  • Second primary cancers. New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
  • Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:

  • diarrhea
  • tiredness
  • muscle and bone pain
  • rash
  • bruising

The most common side effects of IMBRUVICA® in adults with cGVHD include:

  • tiredness
  • bruising
  • diarrhea
  • mouth sores (stomatitis)
  • muscle spasms
  • nausea
  • pneumonia

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

Please see the full Important Product Information.

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: 

  • Mantle cell lymphoma (MCL) who have received at least one prior treatment
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
  • Waldenström’s macroglobulinemia (WM)
  • Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
  • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy

It is not known if IMBRUVICA® is safe and effective in children.

IMPORTANT SIDE EFFECT INFORMATION

USES